CURASIGHT A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.96 DKK | -1.39% |
|
-3.77% | -43.89% |
| Apr. 16 | Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients | CI |
| Apr. 12 | Curasight A/S Announces Board Changes | CI |
| Sales 2024 * | - | Sales 2025 * | 43M 6.17M | Capitalization | 198M 28.43M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | 35M 5.02M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.61 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 4 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.39% | ||
| 1 week | -3.77% | ||
| Current month | -8.62% | ||
| 1 month | -12.63% | ||
| 3 months | -48.92% | ||
| 6 months | -52.57% | ||
| Current year | -43.89% |
1 week
9.00
10.55
1 month
9.0012.40
Current year
8.1619.90
1 year
8.1629.00
3 years
8.1633.60
5 years
8.1644.05
10 years
8.1644.05
| Managers | Title | Age | Since |
|---|---|---|---|
Carsten Nielsen
FOU | Founder | 41 | 12-12-31 |
Jacob Madsen
FOU | Founder | 52 | 12-12-31 |
Andreas Kjaer
FOU | Founder | 61 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kirsten Drejer
BRD | Director/Board Member | 68 | 21-05-03 |
Per Falholt
CHM | Chairman | 65 | 19-12-31 |
| Chief Executive Officer | 57 | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 9.96 | -1.39% | 6,953 |
| 24-04-23 | 10.1 | +0.50% | 4,633 |
| 24-04-22 | 10.05 | 0.00% | 13,286 |
| 24-04-19 | 10.05 | 0.00% | 1,167 |
| 24-04-18 | 10.05 | -0.99% | 1,455 |
End-of-day quote NORDIC GROWTH MARKET, April 23, 2024
More quotes
Curasight A/S is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). The technology provides improved diagnosis and risk stratification in multiple cancer types.
Calendar
2024-05-22
- Q1 2024 Earnings Release
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -43.89% | 28.82M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- CURAS Stock
